AKTS News and Press, Akoustis Technologies Inc.

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today ann...

U.S. FDA Fast Track designation granted to AKY-1189 1 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapies Ongoing Phase 1b trial of AKY-1189 enrolling patients with locally advanced or metastatic urot...

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies,...

2026-01-09 22:05:00 ET Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings.... Read the full article on Seeking Alpha For further details see: U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 9.3% to $2.33 on volume of 358,015,602 shares Mingteng International Corporation Inc. (MTEN) fell 78.9% to $0.1271 on volume of 279,036,858 shares RenX Enterprises Corp. (RENX) ros...

2026-01-09 12:28:51 ET More on Aktis Oncology, Inc., Eli Lilly Eli Lilly's 2026 Resolution: Volume Is The New Price Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum Eli L...

2026-01-09 02:05:07 ET More on Aktis Oncology Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies Lilly partner Aktis targets up to $840M valuation in U.S. IPO Lilly-backed radiopharma startup Aktis seeks U.S. IPO Seeking Alpha’s Q...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

Meta Materials Inc. (MMATQ) is expected to report for quarter end 2024-12-31 ABAXX Technologies Inc. (ABXXF) is expected to report for quarter end 2024-12-31 ClearOne Inc. (CLRO) is expected to report for quarter end 2024-12-31 SSP Group Plc (SSPPF) is expected to report for quarter e...

Cadeler A/S American Depositary Share (each representing four (4) Ordinary Shares) (CDLR) is expected to report $0.34 for Q4 2024 China Mengniu Dairy Company Limited ADR (CIADY) is expected to report for Q4 2024 Atossa Therapeutics Inc. (ATOS) is expected to report $-0.06 for Q4 2024 ...